Roche's Cervical Cancer Portfolio is a comprehensive suite of innovative diagnostic solutions designed to enhance clinical decision-making throughout the cervical cancer screening continuum. This advanced portfolio includes three clinically validated tests focused on identifying women at risk of cervical cancer, improving detection, and confirming high-grade disease through a single screening round. Utilizing cutting-edge HPV and biomarker technology, Roche's products deliver highly sensitive and specific results, empowering laboratory professionals to support healthcare providers with accurate data.

Among the standout offerings, the cobas® HPV test is the first FDA-approved HPV DNA test for various cervical screening indications, providing multiple critical results from a single sample. Additionally, CINtec® PLUS Cytology and CINtec® Histology utilize advanced biomarker technology to assess oncogenic transformation and confirm the presence of cervical lesions, respectively. Roche is committed to providing laboratories with the automation and quality control needed to effectively manage screening volumes, safeguarding women's health against cervical cancer.